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Introduction
The combination of nivolumab + ipilimumab is highly 
effective in the treatment of patients with advanced 
melanoma [1–3] and is being explored in other malig-
nancies. Due to a higher rate of serious initial side 
effects compared to single- agent anti-programmed 
death 1 (PD- 1) therapy, identifying which patients may 
benefit most from the combination is critical. Only 
analyses within randomized trials of combination immu-
notherapy versus anti- PD- 1 monotherapy can truly iden-
tify which patients benefit most from the combination. 
Nonetheless, little is known about which factors to explore 
in these randomized trials. Specifically, to our knowledge, 
no prior studies have been published reporting routine 
clinical laboratory variables as possibly related to out-
comes for nivolumab + ipilimumab combination 
immunotherapy.
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Abstract
Both the combination of nivolumab + ipilimumab and single- agent anti- PD- 1 
immunotherapy have demonstrated survival benefit for patients with advanced 
melanoma. As the combination has a high rate of serious side effects, further 
analyses in randomized trials of combination versus anti- PD- 1 immunotherapy 
are needed to understand who benefits most from the combination. Clinical 
laboratory values that were routinely collected in randomized studies may pro-
vide information on the relative benefit of combination immunotherapy. To 
prioritize which clinical laboratory factors to ultimately explore in these rand-
omized studies, we performed a single- center, retrospective analysis of patients 
with advanced melanoma who received nivolumab + ipilimumab either as part 
of a clinical trial (n = 122) or commercial use (n = 87). Baseline routine labo-
ratory values were correlated with overall survival (OS) and overall response 
rate (ORR). Kaplan–Meier estimation and Cox regression were performed. Me-
dian OS was 44.4 months, 95% CI (32.9, Not Reached). A total of 110 patients 
(53%) responded (CR/PR). Significant independent variables for favorable OS 
included the following: high relative eosinophils, high relative basophils, low 
absolute monocytes, low LDH, and a low neutrophil- to- lymphocyte ratio. These 
newly identified factors, along with those previously reported to be associated 
with anti- PD- 1 monotherapy outcomes, should be studied in the randomized 
trials of nivolumab + ipilimumab versus anti- PD- 1 monotherapies to determine 
whether they help define the patients who benefit most from the combination 
versus anti- PD- 1 alone.
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Many potential biomarkers have been proposed for 
single- agent ipilimumab and anti- PD- 1 therapies. Most 
have involved immunologic aspects of the tumor micro-
environment such as the expression of PD- L1 [4, 5], the 
presence of tumor- infiltrating T cells [6], a high mutational 
load [7, 8], and various specific molecular signatures, 
including loss of phosphatase and tensin homolog (PTEN) 
[9]. Nonetheless, results from biomarker analyses per-
formed on tumors may be inherently limited due to 
immunologic and genetic heterogeneity between tumors 
within an individual patient [10] and may require on- 
treatment immunologic assessment [11].
Basic peripheral blood laboratory variables obtained in 
routine clinical care prior to treatment initiation may also 
be important biomarkers in immunotherapy [12, 13]. As 
these basic variables are routinely collected as part of 
standard care, these variables can be studied in large 
patient populations, including in randomized clinical trials. 
Ultimately, if validated in randomized trials, basic periph-
eral blood laboratory variables could be most easily applied 
to clinical practice.
We therefore evaluated widely available peripheral blood 
laboratory values and basic clinical characteristics in 
patients with advanced melanoma treated with the com-
bination of nivolumab + ipilimumab to determine which 
variables are associated with objective response rate (ORR) 
and overall survival (OS). After defining favorable factors 
for combination immunotherapy, we were then interested 
in a separate, yet related hypothesis that the greatest 
difference in ORR and OS between combination immu-
notherapy and anti- PD- 1 monotherapy exists among 
patients who are not expected to do well with anti- PD- 1 
monotherapy.
Materials and Methods
We performed a retrospective study of 209 patients with 
unresectable stage III or IV melanoma treated with the 
combination of nivolumab + ipilimumab (n = 122 from 
phase I- III clinical trials and the expanded access program; 
n = 87 from commercial use) at Memorial Sloan Kettering 
Cancer Center (MSKCC). This project was approved by 
the MSKCC Institutional Board Review. Baseline peripheral 
blood samples were obtained in the routine course of 
clinical care between 0 and 14 days before the first dose 
of combination immunotherapy.
Five basic laboratory parameters, readily available from 
standard of care laboratory testing, were analyzed: lym-
phocytes, eosinophils, monocytes, neutrophils, and baso-
phils. These five variables were studied in relationship to 
clinical outcomes both as absolute (total number of cells 
in thousands per microliter) and relative (percentage of 
total white blood cells) values. The term “relative” was 
selected for consistency with prior literature on this topic 
[13]. Further, the derived absolute neutrophil- to- 
lymphocyte ratio (NLR) was studied as it has previously 
been associated with outcomes for patients with melanoma 
receiving immunotherapy [14–16]. LDH and M- stage, 
well- known prognostic variables, were additionally ana-
lyzed. LDH was dichotomized using the institutional upper 
limit of normal of ≤ or >246 units per liter (U/L), and 
M- stage was categorized as per American Joint Committee 
on Cancer Staging 7th Edition (M1a, M1b, M1c). M0 
refers to patients who did not have metastatic disease 
but had unresectable stage III disease.
To investigate continuous data as categorical groups 
(high vs. low), optimally selected cut- points for laboratory 
values were estimated based on maximally selected log- 
rank statistics and significance was assessed with Lausen 
and Schumacher’s [17] P- value approximation. P values 
<0.10 were considered statistically significant.
Follow- up time was defined as the time from the first 
dose of treatment to the date of last known contact or 
death. Survival probabilities and median OS with 95% 
confidence intervals (CI) were estimated according to the 
Kaplan–Meier method and compared using log- rank tests. 
Multivariate analysis results from Cox models are described 
by hazard ratios (HRs) with 95% CIs, and P values are 
based on the Wald test.
All responses were investigator assessed as per RECIST 
1.1 criteria [18] except for patients in the phase I trial 
of nivolumab + ipilimumab who had responses assessed 
by the modified World Health Organization Criteria 
(mWHO). Responses for patients off protocol were inves-
tigator assessed. Patient responses were categorized as 
either complete response (CR), partial response (PR), stable 
disease (SD), or progressive disease (PD).
To descriptively report overall survival following the 
nivolumab + ipilimumab combination by the number of 
adverse laboratory variables present, we pooled patients 
with 0–1, 2–3, and 4–5 adverse values. Five adverse values 
were selected which were significant in multivariate analysis. 
Patients who had any missing values were excluded.
Additionally, to descriptively report how patients 
expected to do poorly with anti- PD- 1 monotherapy did 
with combination immunotherapy in our dataset, we 
selected four factors previously reported to be indepen-
dently associated with inferior anti- PD- 1 monotherapy 
ORR and OS: nonlung visceral metastases versus any other 
metastatic site; LDH ratio >2.5 versus ≤2.5 times the upper 
limit of normal; relative lymphocytes <17.5 versus ≥17.5; 
and relative eosinophils <1.5 versus ≥1.5 [13]. We then 
descriptively reported ORR and OS among patients treated 
with combination immunotherapy in our dataset that had 
0, 1, 2, 3, or 4 of these previously described unfavorable 
factors for PD- 1 monotherapy outcomes.
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Results
Patient (n = 209) demographics are shown in Table 1. 
The majority of patients (74.6%) were treatment- naïve. 
Fifty- eight (27.8%) died during follow- up. For patients 
alive at last follow- up (n = 151), the median duration 
of follow- up was 13.1 months. Estimated median OS was 
44.4 months, 95% CI [32.86- NR] (Fig. S1). The overall 
response rate was 52.6% (11% CR and 41.6% PR); 18.6% 
had SD, and 24.4% had PD. Patients who died before 
obtaining a postbaseline scan were considered to have 
PD; 4.3% had unknown response assessment (no post-
baseline scan and no documented death).
As continuous variables, seven laboratory parameters 
were significantly associated with OS. Higher relative lym-
phocytes, relative eosinophils, and relative basophils were 
significantly correlated with improved OS. Higher absolute 
monocytes, absolute neutrophils, and relative neutrophils 
were significantly correlated with worse OS. Increasing 
NLR was also significantly associated with worse OS. 
(Table 2) No individual variables correlated with objective 
response (CR/PR vs. SD/PD).
To facilitate possible ultimate clinical utility and for 
data visualization, the seven continuous variables that were 
significantly associated with OS were then dichotomized 
into high versus low groups based on a cut- point analysis. 
LDH and M- stage were additionally considered as categori-
cal variables as described in Methods. Among these 
categorical variables, five variables were significantly associ-
ated with OS (Table 3, Fig. 1): relative eosinophils ≤1.1 
versus >1.1 (HR 3.48, P < 0.0001), absolute monocytes 
>0.8 versus ≤0.8 (HR 5.56, P < 0.0001), relative basophils 
≤0.6 vs. >0.6 (HR 2.33, P = 0.005), LDH >246 vs. ≤246 
U/L (HR 3.83; P < 0.0001), and NLR >4.73 vs. ≤4.73 
(HR 2.95, P < 0.0001).
All five of these categorical variables retained significance 
in a multivariate model. Low relative eosinophils (HR 
2.38, P = 0.007) and low relative basophils (HR 1.85, 
P = 0.08) were found to be independently associated with 
worse OS. High levels of absolute monocytes (HR 2.75, 
P = 0.01), LDH (HR 3.71, P < 0.0001), and the NLR 
(HR 1.95, P = 0.02) were also independently associated 
with worse OS (Table 4).
Using these five variables which were significant in a 
multivariate model, we then examined patients with 0, 
1, 2, 3, 4, and 5 adverse factors. Due to low numbers 
within each group, we pooled patients with 0–1, 2–3, 
and 4–5 adverse factors (Fig. 2). Descriptively, there was 
an inverse relationship between the number of unfavorable 
variables present and overall survival following nivolumab 
+ ipilimumab.
Next, we wanted to preliminarily describe how patients 
expected to have poorer outcomes with anti- PD- 1 mono-
therapy did with combination immunotherapy in our 
dataset. As described in Methods, we looked at the response 
rates and OS among patients in our dataset with 0, 1, 
2, 3, or 4 previously described poor prognostic variables 
for pembrolizumab monotherapy [13]. There was an inverse 
relationship between the number of unfavorable factors 
for anti- PD- 1 monotherapy and response rate to combi-
nation immunotherapy in our dataset. The same was 
generally true for median OS. (Table 5, Fig. 3).
Discussion
In this study, we define five routine clinical peripheral 
blood laboratory values (relative eosinophils, relative baso-
phils, absolute monocytes, LDH, and NLR) that are inde-
pendently associated with OS in patients treated with the 
combination of nivolumab + ipilimumab. As several of 
these factors such as LDH are established prognostic mark-
ers, we are unable to determine whether these factors are 
predictive of outcome or only prognostic. Several of the 
unfavorable variables (monocytes, LDH, and NLR) as well 
as a favorable variable (eosinophils) are consistent with 
prior studies of ipilimumab or anti- PD- 1 as single agents 
[12–14, 19–22]. It is therefore possible that these cell 
populations have a mechanistic role in immunotherapy 
outcomes.
Eosinophils have been shown to exert favorable effects 
on antitumor immunity in preclinical models. Eosinophils 
Table 1. Patient Demographics (n = 209).
N (%)
Age at treatment start, years

















BRAF/MEK Inhibitors 23 (11)
Other 16 (7.6)
Prior treatment, number of lines
Median (range) (N = 209) 0 (0–7)
Last follow- up status
Dead 58 (27.8)
Alive 151 (72.2)
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may be important mediators in recruiting T cells to the 
tumor microenvironment [23] which may aid immunologic 
tumor control as tumors heavily infiltrated with T cells 
are believed to be more responsive to anti- PD- 1- based 
immunotherapy [6]. Other studies suggest eosinophils play 
a direct role in limiting the process of carcinogenesis and 
can kill tumor cells directly [24].
In addition to eosinophils, we found that patients with 
a high proportion of basophils had better overall survival. 
To our knowledge, basophils have not been previously 
described as a relevant cell population in patients receiv-
ing immune checkpoint inhibitors. Why some cells of 
the myeloid lineage (eosinophils and basophils) but not 
all (monocytes) were associated with favorable effects 
remains unclear. Nonetheless, our finding that monocytes 
were negatively associated with outcomes is consistent 
with other studies [12, 25]. Monocytes may exert unfa-
vorable effects on antitumor immunity via many mecha-
nisms, including giving rise to immunosuppressive 
tissue- resident, M2- macrophages [26]. Many strategies to 
therapeutically target immunosuppressive myeloid popula-
tions are being tested [27], making our findings relevant 
to this area of additional research.
Our study has several limitations. First, our study cohort 
was from a single institution, raising the risk for regional, 
site- specific, or physician treatment bias. Nonetheless, the 
response rate in our study is generally similar to that 
seen in larger phase studies of nivolumab + ipilimumab 
combination therapy [2, 3]. Although the median OS has 
not yet been reached in prior studies of combination 
nivolumab + ipilimumab in treatment- naïve patients, our 
median OS was reached at 44.4 months. This may have 
been the case as we included patients who received treat-
ment off protocol; approximately one- quarter of patients 
also had prior treatment before beginning combination 
immunotherapy. Our study also did not examine whether 
these variables were related to side effects. As prior studies 
have implicated variables such as eosinophilia with toxicity 
[28], this analysis remains of interest for future investiga-
tions in larger populations where associations with these 
variables and specific toxicities may be able to be deter-
mined. Further, the fact that some variables were only 
associated with outcomes when considered as a relative 
percent versus absolute number remains unclear. This 
suggests, however, that the balance among several cell 
populations may be more important than the total number 
in some contexts. Finally, we found significant associations 
between our investigated factors and OS but not ORR. 
Between these two endpoints, we feel that OS is more 
important as the critical question remains whether there 
are any patient populations that derive OS benefits from 
combination immunotherapy versus anti- PD- 1 mono-
therapy. In contrast to OS, most prior analyses of ran-
domized trials have already shown that the ORR is generally 
greater for combination immunotherapy versus PD- 1 
monotherapy across subgroups [3]. Nonetheless, the asso-
ciation of these variables with OS may simply indicate 
they are prognostic, rather than predictive.
Only a randomized trial can answer the question of 
who obtains the greatest benefit from the nivolumab + 
ipilimumab combination compared to single- agent anti- 
PD- 1. Nonetheless, based on these data and previously 
Table 2. Continuous variables examined for association with overall survival.
Factors of Interest Number of Patients Number of Events HR 95% CI P- value
Absolute lymphocytes 209 58 0.85 (.57, 1.26) 0.41
Relative lymphocytes 209 58 0.93 (.90, .97) <0.001*
Absolute eosinophils 209 58 0.19 (.02, 2.39) 0.20
Relative eosinophils 209 58 0.73 (.59, .90) 0.004*
Absolute monocytes 209 58 9.31 (4.07, 21.3) <0.0001*
Relative monocytes 209 58 1.03 (.99, 1.07) 0.21
Absolute neutrophils 209 58 1.20 (1.13, 1.28) <0.0001*
Relative neutrophils 209 58 1.06 (1.02, 1.09) <0.001*
Absolute basophils 209 58 6.64 (.13, 342.8) 0.35
Relative basophils 209 58 0.34 (.15, .79) 0.01*
Neutrophil- to- lymphocyte ratio 209 58 1.19 (1.12, 1.28) <0.0001*
*indicates significant P- value.
Table 3. Univariate analysis of factors associated with overall survival.
Factor of interest Hazard Ratio (95% CI) P- value
Relative eosinophils  
(≤1.1 vs. >1.1)
3.48 (2.02, 6.01) <0.0001
Absolute monocytes  
(>0.8 vs. ≤0.8)
5.56 (2.88, 10.74) <0.0001
Relative basophils  
(≤0.6 vs. >0.6)
2.33 (1.30, 4.19) 0.005
LDH (>246 vs. ≤246) 3.83 (2.19, 6.69) <0.0001
NLR (>4.73 vs. ≤4.73) 2.95 (1.75, 4.97) <0.0001
694 © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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Figure 1. (A–E): Categorical variables which were significantly associated with OS. (A) Patients with relative eosinophils ≤1.1 had worse OS versus 
those with relative eosinophils >1.1 (HR 3.48, P < 0.0001). (B) Patients with absolute monocytes >0.8 had worse OS versus those with absolute 
monocytes ≤0.8 (HR 5.56, P < 0.000). (C) Patients with relative basophils ≤0.6 had worse OS versus those with relative basophils >0.6 (HR 2.33, 
P = 0.0). (D) Patients with LDH >246 U/L had worse OS versus those with LDH ≤246 U/L (HR 3.83; P < 0.0001). (E) Patients with NLR >4.73 had worse 
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published data, it appears that patients who have no 
unfavorable anti- PD- 1 variables (as described in [13]) have 
excellent response rates and OS with either anti- PD- 1 
monotherapy [13] or nivolumab + ipilimumab combina-
tion therapy as shown in our dataset.
However, patients with 2 (ORR 24.3% and median OS 
of 4.2 months with anti- PD- 1 monotherapy in [13] vs. 
ORR 55% and median OS of not reached with combina-
tion in our dataset) or 3 unfavorable variables for anti- 
PD- 1 monotherapy (ORR 7.7% and median OS 1.4 months 
with anti- PD- 1 monotherapy in [13] vs. ORR 43.5% and 
median OS of 7.9 months with combination immuno-
therapy in our dataset) may be the ones who receive the 
greatest benefit from the combination. Nevertheless, these 
preliminary comparisons between nonrandomized retro-
spective cohorts are not ready for clinical application. 
Ongoing randomized studies such as the Checkmate 067 
study of nivolumab + ipilimumab or nivolumab mono-
therapy versus ipilimumab, with recently reported 3-year 
overall survival results [29], provide an opportunity to 
more formally answer this question.
Table 4. Multivariate analysis of factors associated with overall 
survival.
Factor of interest Hazard Ratio (95% CI) P- value
Relative eosinophils  
(≤1.1 vs. >1.1)
2.38 (1.27, 4.46) 0.007
Absolute monocytes  
(>0.8 vs. ≤0.8)
2.75 (1.30, 5.80) 0.01
Relative basophils  
(≤0.6 vs. >0.6)
1.85 (0.94, 3.66) 0.08
LDH (>246 vs. ≤246) 3.71 (2.08, 6.61) <0.0001
NLR (>4.73 vs. ≤4.73) 1.95 (1.11, 3.43) 0.02
Figure 2. Overall survival of patients in our dataset treated with 
nivolumab + ipilimumab combination based upon the number of 
unfavorable variables for nivolumab + ipilimumab defined in this 
manuscript. As the number of unfavorable factors for combination 
immunotherapy outcomes increases, the OS of patients treated with the 
combination in our dataset generally decreases.
Table 5. Response rate and overall survival of patients treated with nivolumab + ipilimumab combination immunotherapy based upon the number of 
unfavorable variables for anti- PD- 1 monotherapy (as described in [13]).
Number of Unfavorable Anti- PD- 1 
Variables
Response Rate with Combination* 
95% CI
Median Overall Survival with Combination (months) 
95% CI
0 (n = 42) 69.1% (52.9%–82.4%) Not Reached (22.0, Not Estimable)
1 (n = 64) 54.7% (41.8%–67.2%) 48.9 (33.0, Not Reached)
2 (n = 40) 55.0% (38.5%–70.7%) Not Reached (Not Estimable)
3 (n = 23) 43.5% (23.2%–65.5%) 7.9 (3.7, 32.4)
4 (n = 6) 16.7% (0.4%–64.1%) 1.5 (0.3, 3.9)
*Calculated by total # of responses/total # of patients with this number of anti- PD- 1 unfavorable variables.
Figure 3. Overall survival of patients in our dataset treated with 
nivolumab + ipilimumab combination based upon the number of 
unfavorable variables for anti- PD- 1 monotherapy (as described in [13]). 
As the number of unfavorable factors for anti- PD- 1 outcomes increased, 
the OS of patients treated with the combination in our dataset generally 
decreased.
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